Terms: = Germ cell tumor AND CIC, ENSG00000079432, 23152, Q96RK0, KIAA0306 AND Treatment
33 results:
1. Genomic alterations of oligodendrogliomas at distant recurrence.
Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
Cancer Med; 2023 Aug; 12(16):17171-17183. PubMed ID: 37533228
[TBL] [Abstract] [Full Text] [Related]
2. Risk factors and a predictive nomogram for hemodynamic instability during adrenalectomy for large pheochromocytomas and paragangliomas: A retrospective cohort study.
Li S; Li Z; Zheng J; Chen X
Eur J Surg Oncol; 2023 Oct; 49(10):106964. PubMed ID: 37369608
[TBL] [Abstract] [Full Text] [Related]
3. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract] [Full Text] [Related]
4. Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials.
Liu APY; Dhanda SK; Lin T; Sioson E; Vasilyeva A; Gudenas B; Tatevossian RG; Jia S; Neale G; Bowers DC; Hassall T; Partap S; Crawford JR; Chintagumpala M; Bouffet E; McCowage G; Broniscer A; Qaddoumi I; Armstrong G; Wright KD; Upadhyaya SA; Vinitsky A; Tinkle CL; Lucas J; Chiang J; Indelicato DJ; Sanders R; Klimo P; Boop FA; Merchant TE; Ellison DW; Northcott PA; Orr BA; Zhou X; Onar-Thomas A; Gajjar A; Robinson GW
Acta Neuropathol; 2022 Oct; 144(4):733-746. PubMed ID: 35982322
[TBL] [Abstract] [Full Text] [Related]
5. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
[TBL] [Abstract] [Full Text] [Related]
6. Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma.
Wong D; Lee TH; Lum A; Tao VL; Yip S
Acta Neuropathol Commun; 2022 May; 10(1):70. PubMed ID: 35526077
[TBL] [Abstract] [Full Text] [Related]
7. Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Benevides Silva FA; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Neurooncol; 2021 Oct; 155(1):13-23. PubMed ID: 34570300
[TBL] [Abstract] [Full Text] [Related]
8. IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology.
Miyake Y; Fujii K; Nakamaura T; Ikegaya N; Matsushita Y; Gobayashi Y; Iwashita H; Udaka N; Kumagai J; Murata H; Takemoto Y; Yamanaka S; Ichimura K; Tateishi K; Yamamoto T
J Neuropathol Exp Neurol; 2021 Feb; 80(3):247-253. PubMed ID: 33432322
[TBL] [Abstract] [Full Text] [Related]
9. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract] [Full Text] [Related]
10. Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors.
Lake JA; Donson AM; Prince E; Davies KD; Nellan A; Green AL; Mulcahy Levy J; Dorris K; Vibhakar R; Hankinson TC; Foreman NK; Ewalt MD; Kleinschmidt-DeMasters BK; Hoffman LM; Gilani A
Pediatr Blood Cancer; 2020 Jan; 67(1):e28028. PubMed ID: 31595628
[TBL] [Abstract] [Full Text] [Related]
11. Chlorotoxin modified morusin-PLGA nanoparticles for targeted glioblastoma therapy.
Agarwal S; Mohamed MS; Mizuki T; Maekawa T; Sakthi Kumar D
J Mater Chem B; 2019 Oct; 7(39):5896-5919. PubMed ID: 31423502
[TBL] [Abstract] [Full Text] [Related]
12. The soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cells.
Shidal C; Inaba JI; Yaddanapudi K; Davis KR
Oncotarget; 2017 Apr; 8(15):25525-25541. PubMed ID: 28424421
[TBL] [Abstract] [Full Text] [Related]
13. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
[TBL] [Abstract] [Full Text] [Related]
14. Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells.
Shidal C; Al-Rayyan N; Yaddanapudi K; Davis KR
Oncotarget; 2016 Dec; 7(51):84128-84141. PubMed ID: 27566591
[TBL] [Abstract] [Full Text] [Related]
15. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.
Tanboon J; Williams EA; Louis DN
J Neuropathol Exp Neurol; 2016 Jan; 75(1):4-18. PubMed ID: 26671986
[TBL] [Abstract] [Full Text] [Related]
16. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, cic and FUBP1.
Cahill DP; Louis DN; Cairncross JG
CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
[TBL] [Abstract] [Full Text] [Related]
17. TCF12 is mutated in anaplastic oligodendroglioma.
Labreche K; Simeonova I; Kamoun A; Gleize V; Chubb D; Letouzé E; Riazalhosseini Y; Dobbins SE; Elarouci N; Ducray F; de Reyniès A; Zelenika D; Wardell CP; Frampton M; Saulnier O; Pastinen T; Hallout S; Figarella-Branger D; Dehais C; Idbaih A; Mokhtari K; Delattre JY; Huillard E; Mark Lathrop G; Sanson M; Houlston RS;
Nat Commun; 2015 Jun; 6():7207. PubMed ID: 26068201
[TBL] [Abstract] [Full Text] [Related]
18. tumor-specific mutations in low-frequency genes affect their functional properties.
Erdem-Eraslan L; Heijsman D; de Wit M; Kremer A; Sacchetti A; van der Spek PJ; Sillevis Smitt PA; French PJ
J Neurooncol; 2015 May; 122(3):461-70. PubMed ID: 25694352
[TBL] [Abstract] [Full Text] [Related]
19. Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management.
Sahebjam S; McNamara MG; Mason WP
CNS Oncol; 2013 Jul; 2(4):351-8. PubMed ID: 25054579
[TBL] [Abstract] [Full Text] [Related]
20. Novel cic point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing.
Eisenreich S; Abou-El-Ardat K; Szafranski K; Campos Valenzuela JA; Rump A; Nigro JM; Bjerkvig R; Gerlach EM; Hackmann K; Schröck E; Krex D; Kaderali L; Schackert G; Platzer M; Klink B
PLoS One; 2013; 8(9):e76623. PubMed ID: 24086756
[TBL] [Abstract] [Full Text] [Related]
[Next]
